R 
Raily Aesthetic Medicine International Holdings 2135.HK · HKD
Health Care · HKEX · 🇭🇰 Hong Kong
0.09
—
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥184.5m
FY2017FY2025
Net income
CN¥1.8m
FY2017FY2025
Free cash flow
CN¥32.0m
FY2017FY2025
Shareholders' equity
CN¥107.9m
FY2017FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥184.5m | CN¥170.7m | CN¥162.1m | CN¥140.9m | CN¥161.3m | CN¥140.9m | CN¥163.7m | CN¥158.9m | CN¥112.9m |
| Gross profit | CN¥75.7m | CN¥61.1m | CN¥61.2m | CN¥57.2m | CN¥59.7m | CN¥68.6m | CN¥86.5m | CN¥92.5m | CN¥74.5m |
| Research and development | CN¥2.0m | CN¥613,844 | CN¥1.4m | CN¥1.7m | — | — | — | — | — |
| Operating income | CN¥5.0m | −CN¥53.5m | −CN¥28.3m | −CN¥17.0m | −CN¥18.4m | CN¥8.6m | CN¥15.4m | CN¥29.1m | CN¥24.7m |
| Net income | CN¥1.8m | −CN¥50.7m | −CN¥27.8m | −CN¥13.6m | −CN¥15.1m | CN¥3.6m | CN¥8.5m | CN¥17.9m | CN¥17.4m |
| Diluted earnings per share | 0.00 | -0.09 | -0.07 | -0.03 | -0.03 | 0.00 | 0.03 | 0.03 | 0.03 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥237.8m | CN¥214.0m | CN¥234.2m | CN¥259.1m | CN¥295.1m | CN¥233.2m | CN¥156.8m | CN¥117.8m | CN¥82.1m |
| Cash and short-term investments | CN¥57.8m | CN¥24.7m | CN¥34.1m | CN¥67.4m | CN¥104.2m | CN¥136.0m | CN¥42.3m | CN¥20.4m | CN¥9.4m |
| Total liabilities | CN¥139.5m | CN¥132.2m | CN¥120.7m | CN¥117.1m | CN¥139.0m | CN¥73.3m | CN¥77.1m | CN¥102.8m | CN¥66.4m |
| Debt | CN¥59.2m | CN¥48.3m | CN¥44.3m | CN¥41.3m | CN¥57.7m | CN¥23.2m | CN¥22.9m | CN¥27.2m | CN¥15.3m |
| Shareholders' equity | CN¥107.9m | CN¥89.2m | CN¥118.2m | CN¥142.2m | CN¥152.6m | CN¥159.1m | CN¥79.7m | CN¥15.0m | CN¥16.3m |
| Shares outstanding | 556m | 557m | 418m | 481m | 481m | 2,055m | 307m | 557m | 557m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥34.7m | CN¥5.1m | CN¥6.9m | −CN¥1.9m | −CN¥2.1m | CN¥12.1m | CN¥14.5m | CN¥32.1m | CN¥34.5m |
| Capital spending | −CN¥2.7m | −CN¥38.2m | −CN¥15.4m | −CN¥16.1m | −CN¥13.5m | −CN¥7.4m | −CN¥11.4m | −CN¥15.1m | −CN¥2.6m |
| Free cash flow | CN¥32.0m | −CN¥33.0m | −CN¥8.6m | −CN¥18.1m | −CN¥15.6m | CN¥4.8m | CN¥3.1m | CN¥17.0m | CN¥31.9m |
| Dividends paid | — | — | — | — | — | — | −CN¥16.1m | −CN¥12.6m | −CN¥12.6m |
Latest quarters
By quarter end
| Jun 2026 | Dec 2025 | Jun 2025 | Dec 2024 | Jun 2024 | Dec 2023 | Sept 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥114.9m | CN¥103.1m | CN¥84.6m | CN¥70.1m | CN¥100.6m | CN¥78.6m | CN¥45.9m | CN¥87.3m |
| Gross profit | CN¥44.1m | CN¥47.8m | CN¥29.1m | CN¥19.6m | CN¥41.5m | CN¥27.8m | CN¥16.2m | CN¥34.9m |
| Operating income | CN¥5.9m | CN¥12.5m | −CN¥7.6m | −CN¥19.6m | CN¥3.5m | −CN¥17.3m | −CN¥10.1m | −CN¥2.5m |
| Net income | CN¥4.1m | CN¥9.3m | −CN¥7.6m | −CN¥49.3m | −CN¥1.4m | −CN¥25.9m | −CN¥15.1m | −CN¥2.0m |
| Diluted earnings per share | 0.01 | 0.02 | -0.01 | -0.09 | -0.00 | -0.06 | -0.04 | -0.00 |
| Cash from operations | −CN¥1.0m | CN¥29.0m | CN¥6.0m | CN¥3.0m | CN¥1.0m | — | — | CN¥6.0m |
| Capital spending | −CN¥24.0m | −CN¥1.0m | −CN¥1.0m | −CN¥3.0m | −CN¥3.0m | −CN¥8.0m | −CN¥4.0m | −CN¥7.0m |
| Free cash flow | −CN¥25.0m | CN¥28.0m | CN¥5.0m | CN¥0 | −CN¥2.0m | — | — | −CN¥1.0m |
| Total assets | CN¥236.9m | CN¥237.8m | CN¥240.9m | CN¥214.0m | CN¥278.1m | CN¥234.2m | CN¥273.6m | CN¥261.9m |
| Cash and short-term investments | CN¥48.7m | CN¥57.8m | CN¥35.7m | CN¥24.7m | CN¥35.0m | CN¥34.1m | CN¥39.8m | CN¥51.1m |
| Debt | CN¥24.7m | CN¥59.2m | CN¥55.7m | CN¥48.3m | CN¥47.8m | CN¥44.3m | CN¥17.3m | CN¥17.1m |
| Shareholders' equity | CN¥112.2m | CN¥107.9m | CN¥98.0m | CN¥89.2m | CN¥134.8m | CN¥118.2m | CN¥138.1m | CN¥142.5m |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 8.9% | 5.2% | — |
| Operating income | — | -10.2% | — |
| Net income | — | -12.9% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 38.5% | 38.8% | 39.9% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Price to earnings | 41.1 | -1.1 | -6.6 | -25.5 | -43.1 | — |
| Price to sales | 0.4 | 0.3 | 1.2 | 2.5 | 4.1 | 25.6 |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years.
- 5-to-1 reverse split · 19 Mar 2024
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.